BioSpace News Archive

Global Blood Therapeutics, Inc. and the Sickle Cell Disease Association of America, Inc. announced that they will host the 8th Annual Sickle Cell Disease (SCD) Therapeutics Conference on Tuesday, September 10, 2019, at The Westin Washington, D.C. U.S. Representative Robin Kelly, chair of the Congressional Black Caucus Health Braintrust, will deliver the keynote address.

Motif Bio plc announces that its lender, Hercules Capital, Inc., has agreed to amend the Company’s loan and security agreement such that the next amortisation date is postponed from September 1 to October 1, 2019.

Global Blood Therapeutics, Inc. announced that it will present at the 2019 Morgan Stanley Global Healthcare Conference in New York City on Monday, September 9, 2019, at 2:50 p.m. Eastern Time.

Strengthening Azelis’ focus on application and formulation support

Biofidelity Ltd announces it has secured £0.75 million seed financing, following its formation earlier this year.

This is part of the continuous work to strengthen the control position of the company’s own assets.

Research is enabling precision medicine to change the future for an increasing number of Canadians facing blood cancer diagnoses

Genentech, a member of the Roche Group, announced that new data across its neuroscience portfolio will be presented at the 35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis from September 11-13 in Stockholm.

NorthSea Therapeutics B.V. announces the appointment of Mats Blom as Chief Financial Officer.

Repare Therapeutics, a precision oncology company targeting specific vulnerabilities of tumors in genetically defined patient populations, announced the completion of a US$82.5 million Series B financing.